CDKL5 Deficiency Disorder – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

CDKL5 deficiency disorder is a genetic disorder that causes seizures, developmental delay, and severe intellectual disability. Seizures typically begin within a few months after birth and are difficult to control with medications. Most children have 1 to 5 seizures every day. It is an X-linked dominant disorder

·       This disorder includes many of the features of classic Rett syndrome (including developmental problems, loss of language skills, and repeated hand wringing or hand washing movements), but also causes recurrent seizures beginning in infancy

·       Some CDKL5 mutations change a single protein building block (amino acid) in a region of the CDKL5 protein that is critical for its kinase function. Other mutations lead to the production of an abnormally short, nonfunctional version of the protein

·       There are currently no approved drugs to treat CDKL5 Deficiency, save for Anti-Epileptic Drugs (AEDs) to treat the epileptic seizures

·       The anti-epileptic drugs have limited efficacy, pointing to a strong need to develop new treatment strategies for patients

 

The competitive landscape of CDKL5 Deficiency Disorder includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of CDKL5 Deficiency Disorder across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

CDKL5 Deficiency Disorder Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: CDKL5 Deficiency Disorder – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          ganaxolone       Marinus Pharmaceuticals           Phase 3

2          Soticlestat         Ovid Therapeutics Inc.   Phase 2

3          STK-001           Stoke Therapeutics, Inc Phase 2

4          ZX008  Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.       Phase 2

5          EPX-100 (Clemizole HCl)           Epygenix           Phase 2

6          GWP42003-P    GW Research Ltd          Phase 3

7          Lorcaserin         Eisai Inc.          Phase 3

8          Cannabidiol Oral Solution           INSYS Therapeutics Inc Phase 3

 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033